The phase IIIb PONENTE trial* aims to assess if adults with severe eosinophilic asthma who are treated with benralizumab can safely reduce their doses of oral corticosteroid (OCS) therapy, while still maintaining asthma control.
The anti-interleukin-5 receptor alpha monoclonal antibody benralizumab significantly reduced the rates of severe exacerbations (SevEx) and asthma worsening episodes (AWE) in patients with severe asthma, leading to a reduction in the risk of overall CompEx* events, according to a post hoc analysis of the phase III SIROCCO** and CALIMA*** trials presented at ATS 2019.
Using budesonide/formoterol as needed was as effective as budesonide maintenance therapy in preventing exacerbations but with a lower exposure to ICS among patients with mild asthma, including adolescent patients and regardless of prior treatment used, according to two subgroup analyses of the SYGMA* 1 and 2 studies presented at the ATS 2019 Congress.
Influenza vaccination effectively reduced the risk of influenza-related hospitalizations in patients with chronic obstructive pulmonary disease (COPD) compared with those who were not vaccinated, according to a study presented at ATS 2019.
Rupatadine at either 10 or 20 mg delivers superior improvements in nasal and ocular symptoms of seasonal allergic rhinitis compared with placebo, with both doses well tolerated by adult and adolescent patients, according to the results of a phase III trial.